Novo Nordisk will open its $100 million, 200,000-square-foot expanded facility in Clayton to meet the country's increasing demand for FlexPen(R), the world's number one selling popular prefilled insulin pen.
The event marks the second expansion in three years of the company's only insulin manufacturing facility in the United States, doubling the company's domestic insulin filling capabilities and initiating the first domestic production of FlexPen(R). As a result, more than 50 jobs have been created. To date, Novo Nordisk has expanded its workforce in Clayton to 400.
The company has a Triple Bottom Line commitment to social and environmental responsibility. To date, more than 3,000 adults have completed courses at the Johnston County Workforce Development Center, an award-winning learning center made possible through donations, including a land donation for the center from Novo Nordisk.